Navigation Links
F. Duwaine Townsen Joins SpectraScience Board of Directors
Date:7/28/2009

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that F. Duwaine Townsen, Co-Founder/Managing Director of EndPoint Late-Stage Fund has joined its Board of Directors.

He began his career with Arthur Young & Company following graduation from San Diego State University in 1961. He later became a founder and Chief Financial Officer of Oceanographic Engineering Corporation guiding the company to profitability and its sale to Dillingham Corporation. Mr. Townsen was then promoted to President of the newly formed Ocean Operations Division of Dillingham in 1967.

Mr. Townsen left Dillingham Corporation in 1969 to form Kay Laboratories, Inc., a medical device company, as Chief Financial Officer. He was appointed to CEO and Chairman in 1974 and guided the Company through its IPO in 1978 and sale to American Hospital Supply Corporation in 1981.

In 1982, Mr. Townsen co-founded the Ventana Growth Funds, a group of four venture capital funds, one leasing fund and one joint venture strategic fund, and served as the group's Managing Partner. Ventana Growth Fund was the first San Diego-based venture capital fund dedicated to the Southern California market. Ventana Growth Funds invested primarily in early and middle stage life science, high-tech and telecommunications companies.

In 1998 Mr. Townsen co-founded and was the Managing Partner of EndPoint Late-Stage Fund located in San Diego. This fund invested exclusively in late-stage life science companies that have reached a stage where product, sales and liquidity can be forecast within a reasonable period of time.

In a career that spans more that 40 years in San Diego, he has worked with over 100 emerging companies, primarily in the areas of biotechnology, healthcare and high-tech. As a CPA, former CE
'/>"/>

SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
2. Richard Greco Joins Mediware Board
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
5. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
6. Nick Childs Joins Grey New York as Director of Content Development
7. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
8. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
9. NASN Joins Partnership to Fight Chronic Disease
10. AstraZeneca Joins Local Walking Movement
11. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 1New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 2New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 3New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 4Texcel Medical Expands Medical Device Development 26 Manufacturing Capabilities With New Personnel Nearly 241 Million in Capital Investments 13501 1Texcel Medical Expands Medical Device Development 26 Manufacturing Capabilities With New Personnel Nearly 241 Million in Capital Investments 13501 2Texcel Medical Expands Medical Device Development 26 Manufacturing Capabilities With New Personnel Nearly 241 Million in Capital Investments 13501 3Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 1Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 2Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 3